Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know

Bristol Myers Squibb (BMY) is attracting investor attention, with shares up 7.3% in the past month versus the S&P 500's 6.9% gain. While the current fiscal year EPS is projected to increase 495.7%, revenue is expected to decline by 4.1%, and next year's EPS is forecasted to decrease by 11.5% alongside a 7.4% revenue drop. The stock currently holds a Zacks Rank #3 (Hold), suggesting near-term performance in line with the broader market; however, the company is considered undervalued based on Zacks' Value Style Score.

Analysis

Bristol Myers Squibb (BMY) has recently attracted significant investor attention, with its shares delivering a +7.3% return over the past month, outperforming the Zacks S&P 500 composite's +6.9% gain, though lagging the +11.4% rise in the Zacks Medical - Biomedical and Genetics industry. Despite a robust history of exceeding expectations, having beaten consensus EPS estimates in each of the trailing four quarters and topped revenue estimates consistently over the same period—with the last reported quarter showing revenues of $11.2 billion (-5.6% YoY, a +4.38% surprise) and EPS of $1.8 (+19.21% surprise)—the forward outlook presents challenges. Current quarter earnings are anticipated at $1.67 per share, a -19.3% year-over-year decrease, with the consensus estimate unchanged in the last 30 days. While the current fiscal year consensus EPS of $6.85 reflects a substantial +495.7% year-over-year increase (this estimate has seen a slight -0.6% downward revision recently), projections for the next fiscal year indicate an 11.5% decline in EPS to $6.06, with that estimate also revised down by -0.3% in the past month. Revenue forecasts are similarly subdued, with consensus sales for the current quarter at $11.32 billion (-7.2% YoY), and full-year estimates pointing to declines of -4.1% for the current fiscal year ($46.31 billion) and -7.4% for the next ($42.87 billion). Consequently, BMY holds a Zacks Rank #3 (Hold), suggesting near-term performance in line with the broader market, although its 'A' grade on the Zacks Value Style Score indicates it is currently trading at a discount compared to its peers.

Key Decisions for Investors

• Investors should carefully consider the contrast between BMY's recent positive stock momentum and strong historical earnings performance against the backdrop of analyst forecasts predicting declining revenues and earnings per share in the coming quarters and the next fiscal year.
• The Zacks Rank #3 (Hold) suggests that BMY may perform in line with the broader market in the near term, while its 'A' Value Style Score indicates a potential undervaluation relative to peers, which could appeal to value-focused investors willing to look past near-term growth headwinds.
• It is advisable to closely monitor upcoming earnings releases and any further revisions to consensus estimates for both revenue and EPS, as these will be critical in assessing the company's ability to navigate its growth challenges and justify its current valuation.